Thesis icon

Thesis

Enhancing oncolytic virotherapy of glioblastoma by targeting innate immune ligands with a bispecific T cell engager

Abstract:

Glioblastoma (GBM) is a highly aggressive brain tumour in adults, often becoming resistant towards conventional therapy of radiotherapy and temozolomide (TMZ) chemotherapy. The oncolytic herpes simplex virus-1 (oHSV- 1) G207 is a promising approach for GBM immunotherapy, capable of selective infection, replication and causing cell lysis within GBM but not healthy cells. However, G207 has demonstrated only limited efficacy in GBM clinical trials.

The Natural Killer Group 2 Member D ...

Expand abstract

Actions


Access Document


Files:

Authors


More by this author
Division:
MSD
Department:
Oncology
Role:
Author

Contributors

Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Role:
Supervisor
ORCID:
0000-0003-3825-0841
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Role:
Supervisor
Institution:
University of Oxford
Division:
MSD
Department:
Clinical Neurosciences
Role:
Supervisor
More from this funder
Name:
Brain Research UK
Funder identifier:
http://dx.doi.org/10.13039/100013790
Grant:
STU1617-02
Type of award:
DPhil
Level of award:
Doctoral
Awarding institution:
University of Oxford
DOI:

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP